Sporadic p53 mutations and absence of ras mutations in glioblastomas

被引:13
作者
Gömöri, É
Dóczi, T
Pajor, L
Matolcsy, A
机构
[1] Univ Pecs, Sch Med, Dept Pathol, H-7643 Pecs, Hungary
[2] Univ Pecs, Sch Med, Dept Neurosurg, H-7643 Pecs, Hungary
关键词
glioblastoma; p53 tumour suppressor gene mutation; PCR-SSCP sequence analysis; ras-oncogenes;
D O I
10.1007/s007010050348
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
As concerns human adult brain neoplasms, the biological behaviour of glioblastoma, a high-grade neuro-ectodermal tumour, is among the most disadvantageous. Glioblastoma may develop either as a primary tumour without clinical and histological evidence of a prior precursor lesion, or as the final stage of malignant transformation of a low-grade or anaplastic astrocytoma. There are conflicting reports in connection with the association of the p53 tumour suppressor gene mutation with the clinical and histological progression of gliomas. Previous studies likewise led to contradictory results concerning the significance of ras oncogenes in different histological malignancies, and especially in neuro-epithelial tumours. The possible roles of p53 and ras gene alterations in the development of "primary'' and "transformed" glioblastomas were studied in this work. Eighteen tumours were investigated by means of immunohistochemistry and polymerase chain reaction-assisted-single strand conformation polymorphism (PCR-SSCP) sequence analysis in a search for molecular genetic differences between primary and transformed glioblastomas. An increased incidence of p53-immunopositive cells was observed in both types of glioblastomas but there was no significant difference between the transformed tumours and the primary form. All samples were screened for point mutation in codons 12 and 61 of the H-, K-, and N-ras oncogenes and exons 5-8 of the p53 gene. No aberrant band or mutation was found in the H-, K- and N-ras oncogenes. Aberrant bands were seen in only 2 (11%) of the 18 rumours in the SSCP analyses of exons 6 and 8. Sequence analysis of the 2 abnormal cases revealed G --> C transmission in the second nucleotide of codon 280 on exon 8, which resulted in a change in the encoded amino acid from arginine to threonine (case 15). A ttagtct --> ttggtct transmission on intron 5 (case 8) was also found. No genetic difference could be identified between the primary and the transformed glioblastoma forms as concerns their p53 and ras oncogenes. There are two possible explanations for these findings: (a) The p53 and ras gene mutations were not primary events in the morphological transformations. Alterations in these genes may therefore take place at an early stage in glioma progression. (b) The different genetic changes may accumulate during glioblastoma development. These specific genetic events may additionally play a role in multistep tumourigenesis.
引用
收藏
页码:593 / 599
页数:7
相关论文
共 51 条
[1]  
ALI IU, 1994, CANCER RES, V54, P1
[2]  
Arvanitis D, 1991, In Vivo, V5, P317
[3]   IDENTICAL MUTATIONS OF THE P53 TUMOR-SUPPRESSOR GENE IN THE GLIOMATOUS AND THE SARCOMATOUS COMPONENTS OF GLIOSARCOMAS SUGGEST A COMMON ORIGIN FROM GLIAL-CELLS [J].
BIERNAT, W ;
AGUZZI, A ;
SURE, U ;
GRANT, JW ;
KLEIHUES, P ;
HEGI, ME .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1995, 54 (05) :651-656
[4]   ENHANCED EXPRESSION OF 4 CELLULAR ONCOGENES IN A HUMAN GLIOBLASTOMA CELL-LINE [J].
BLIN, N ;
MULLERBRECHLIN, R ;
CARSTENS, C ;
MEESE, E ;
ZANG, KD .
CANCER GENETICS AND CYTOGENETICS, 1987, 25 (02) :285-292
[5]   PREVALENCE OF RAS GENE-MUTATIONS IN HUMAN COLORECTAL CANCERS [J].
BOS, JL ;
FEARON, ER ;
HAMILTON, SR ;
VERLAANDEVRIES, M ;
VANBOOM, JH ;
VANDEREB, AJ ;
VOGELSTEIN, B .
NATURE, 1987, 327 (6120) :293-297
[6]  
BOS JL, 1989, CANCER RES, V49, P4682
[7]   A VARIATION IN THE STRUCTURE OF THE PROTEIN-CODING REGION OF THE HUMAN-P53 GENE [J].
BUCHMAN, VL ;
CHUMAKOV, PM ;
NINKINA, NN ;
SAMARINA, OP ;
GEORGIEV, GP .
GENE, 1988, 70 (02) :245-252
[8]   EFFECT OF RETINOIC ACID ON P21(RAS) AND REGULATORS OF ITS ACTIVITY IN NEUROBLASTOMA [J].
BURCHILL, SA ;
BERRY, PA ;
LEWIS, IJ .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (04) :476-481
[9]  
Cho JY, 1997, CANCER-AM CANCER SOC, V79, P462, DOI 10.1002/(SICI)1097-0142(19970201)79:3<462::AID-CNCR6>3.0.CO
[10]  
2-K